BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp

Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report)'s stock price was up 5.3% on Wednesday. The stock

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmu

More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48 42% of telitacicept-

Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Topline results from UPSTREAM MG's 24-week primary endpoint remain on track for first half of 2027 G

BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology com

Bank of America Corp DE increased its position in Vor Biopharma Inc. (NASDAQ: VOR) by 28,408.1% duri

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology com

Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the pr

Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.80) per share which missed the analyst c

Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.16) per share which missed the analyst c

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis p

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp

BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp

Vor Biopharma (VOR) has transformed into a late-stage autoimmune drug developer, focusing on telitac

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp

Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for

The conditional approval is supported by positive efficacy and safety data from RemeGen's comple

First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in Chi

First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)  Approval based on p

BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnolo

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology compa

Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and up

U.S. stocks lower, Nasdaq falls 1%. Oxford Industries up 11.2% on strong earnings, raised dividend.

XCUR: 176% | Exicure shares are trading higher after the company announced results from its complete